간세포암의 치료후의 진단과 후속초치에 있어 혈청 PIVKA-II의 효험
Efficacy of Serum PIVKA-II in the Diagnosis and Follow-up after Treatment of Hepatocellular Carcinoma
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
.
Abstract
It is a very important diagnosis and evalution of Hepatocellular carcinoma (HCC) in Korea where hepatitis B-virus is endemic. Protein induced by vitamin K absence or antagonist II (PIVKA-II) appears to be a useful tumor marker. This study was purposed to investigate usefulness of PIVKA-II in the diagnosis and fallow-up after treatment of HCC. A total of 418 patients were included in 187 patients (44.7%) of HCC, 83 patients (19.9%) of liver cirrhosis, 74 patients (17.7%) of chronic hepatitis and 74 patients (17.7%) of other liver diseases with serum PIVKA-II levels by Hicatch PIVKA-II kit. PIVKA-II level were analysed for difference of groups and the comparison of treatment responses. The sensitivity and specificity of PIVKA-II in the diagnosis of HCC were 80.2%, 87.0% at the cut-off value of 40 mAU/mL. There were statistically significant difference between the HCC and other groups (p <0.001), before and after PIVKA-II levels after treatment in HCC (p <0.001). PIVKA-II can be used as a useful tumor marker for patients with HCC, especially early diagnosis in high risk groups, treatment response assesment and monitoring of recurrence.
참고문헌 (20)
- Chen DS, "Small hepatocellular carcinoma:A clinicopathological study in thirteen patients", Am J Gastroenterol, 83, pp.1109~1119 (1982)
- Fugiyama S, "Plasma abnormal prothrombin (des-γ-carboxy prothrombin) as a marker of hepatocellular carcinoma", Am J Cancer, 61, pp.1621~1628 (1988)
- 김도영, "간세포암의 진단과 재발판정에서 PIVKA-II의 유용성", 대한내과학회지, 69(1), pp.39~45 (2005), 대한내과학회
- Kim J, "Elevated plasma osteopontin levels in patients with hepatocellular carcinoma", Am J Gastroenterol, 101, pp.2051~2059 (2006)
- Liebman HA, "Des-gamma-carboxy (abnormal) prothrombin as a serum maker of primary hepatocellular carcinoma", N Engl J Med, 310, pp.1427~1431 (1984)
- Nakao A, "Clinical evaluation of plasma abnormal prothrombin (des-γ-carboxy prothrombin) in hepatobiliary malignancies and other disease", Am J Gastroenterol, 86, pp.62~66 (1991)
- Nanashima A, "Modified CLIP using PIVKA-II for evaluating prognosis after hepatectomy for hepatocellular carcinoma", Eur J Sur Oncol, 29, pp.735~742 (2003)
- Okuda K., "The Liver Cancer Study Group of Japan. Primary liver cancer in Japan", Am J Cancer, 45, pp.2663~2669 (1980)
- Okuda H, "Measurement of serum levels of des-γ-carboxy prothrombin in patients with hepatocellular carcinoma by a revised enzyme immunoassay kit with increased sensitivity", Am J Cancer, 85, pp.812~818 (1999)
- Okuda H, "Serum levels of desgamma-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma", Am J Cancer, 88, pp.544~549 (2000)
- Saitoh S, "Serim des-γ-carboxy prothrombin concentrantion determined by the avidin-biotin complex method in small hepatocellular carcinoma", Am J Cancer, 74, pp.2918~2923 (1994)
- Sherman M., "Alphafetoprotein: an obituary", J Hepatol, 34, pp.603~605 (2001)
- Wang CS, "Usefulness of serum des-γ-carboxy prothrombin in detection of hepatocellular carcinoma", World J Gastroenterol, 11, pp.6115~6119 (2005)
- Weits IC, "Des-γ-carboxy (abnormal) prothrombin and hepatocellular carcinoma: A critical review", Am J Hepatology, 18, pp.990~997 (1993)
- 윤영준, "간세포암종의 진단 및 치료 후 추적 관찰에서 혈청 PIVKA-II의 임상적 효용성", Clinical and Molecular Hepatology, 8(2002), pp.465~471 (2002), 대한간학회
- 김철, "간세포암종의 진단에 있어서 자동화분석기로 측정한 AFP-L3와 PIVKA-II의 임상적 유용성", 대한간학회지, 7, pp.467~474 (2001)
- 보건복지부, "5대 사망 질병의 사회 경제적 비용 수계", 보건복지 포럼, ~ (2003)
- 안상훈, "한국인에서 간암발생의 위험요인분석", 대한내과학회지, 60, pp.123~130 (2001)
- 한광협, "간암 고위험군의 조기진단을 위한선별검사(Screening) 방안 수립 및 효과 평가 연구", 대한 암학회지, 32, pp.1084~1092 (2000)
- 한광협, "원발성 간암환자의 간염 바이러스감염유형에 다른 임상 양상 및 예후", 대한내과학회지, 60, pp.22~31 (2001)